Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers

Clinical Cancer Research

Volumn 16, Issue 18, 2010, Pages 4532-4542

  Redon, Christophe E ^a   Nakamura, Asako J ^a   Zhang, Yong Wei ^a   Ji, Jiuping ^b   Bonner, William M ^a   Kinders, Robert J ^b   Parchment, Ralph E ^b   Doroshow, James H ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; AZD 7762; BATRACYLIN; BLEOMYCIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HISTONE H2AX; HYDROXYUREA; IMATINIB; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLY(ADENOSINE DIPHOSPHATE RIBOSE); SJG 136; TEMOZOLOMIDE; TIRAPAZAMINE; TRABECTEDIN; UNCLASSIFIED DRUG; VIRONOSTAT; ANTINEOPLASTIC AGENT; H2AFX PROTEIN, HUMAN; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHARMACOLOGICAL BIOMARKER; TUMOR MARKER;

CANCER RADIOTHERAPY; CANCER THERAPY; CHROMATIN; DNA DAMAGE; DNA METABOLISM; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLOGY; PHYSIOLOGY; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DNA DAMAGE; HISTONES; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASMS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956686608     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0523     Document Type: Review

References (104)

1. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-9.
2. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566-80. (Pubitemid 37361748)
3. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002;12:162-9. (Pubitemid 34219488)
4. Bonner WM, Redon CE, Dickey JS, et al. γH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
5. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
6. Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. Science 2002;296:922-7.
7. Cha H, Lowe JM, Li H, et al. Wip1 directly dephosphorylates γ-H2AX and attenuates the DNA damage response. Cancer Res 2010;70:4112-22.
8. Moon SH, Nguyen TA, Darlington Y, Lu X, Donehower LA. Dephosphorylation of γH2AX by WIP1: An important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle 2010:9. Epub 2010 Jun 12.
9. Douglas P, Zhong J, Ye R, Moorhead GB, Xu X, Lees-Miller SP. Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates γ-H2AX. Mol Cell Biol 2010;30:1368-81.
10. Nakada S, Chen GI, Gingras AC, Durocher D. PP4 is a γ H2AX phosphatase required for recovery from the DNA damage checkpoint. EMBO Rep 2008;9:1019-26.
11. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. γ-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005;20:801-9. (Pubitemid 41740701)
12. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
13. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68. (Pubitemid 29425344)
14. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 2005;19:1951-67.
15. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28. (Pubitemid 44036457)
16. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.
17. Ju BG, Lunyak VV, Perissi V, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006;312:1798-802. (Pubitemid 43962898)
18. Lis JT, Kraus WL. Promoter cleavage: a topoIIbeta and PARP-1 collaboration. Cell 2006;125:1225-7.
19. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963;11:39-43.
20. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009;37:3723-38.
21. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71. (Pubitemid 28240528)
22. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003;2:955-69.
23. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33. (Pubitemid 37441922)
24. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004;279:55117-26. (Pubitemid 40066505)
25. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother Oncol 2009;92:310-5.
26. Ahmed EA, de Boer P, Philippens ME, Kal HB, de Rooij DG. Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids. Mutat Res 2010;683:84-90.
27. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
28. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
29. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009;12:153-6.
30. Annunziata CM, O'Shaughnessy J. Poly(ADP-Ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010;16:4517-26.
31. Oka K, Tanaka T, Enoki T, et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 2010;9:246-52.
32. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
33. Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygoty: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60.
34. Wang LH, Pfister TD, Parchment RE, et al. Monitoring drug-induced γH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010;16:1073-84.
35. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010;20:96-9.
36. Lobrich M, Rief N, Kuhne M, et al. In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. Proc Natl Acad Sci U S A 2005;102:8984-9.
37. Redon CE, Dickey JS, Bonner WM, Sedelnikova OA. γ-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin. Adv Space Res 2009;43:1171-8.
38. Szeto YT, Benzie IF, Collins AR, et al. A buccal cell model comet assay: development and evaluation for human biomonitoring and nutritional studies. Mutat Res 2005;578:371-81.
39. Rothkamm K, Horn S. γ-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita 2009;45:265-71.
40. Yoon AJ, Shen J, Wu HC, et al. Expression of activated checkpoint kinase 2 and histone 2AX in exfoliative oral cells after exposure to ionizing radiation. Radiat Res 2009;171:771-5.
41. Gho CG, Braun JE, Tilli CM, Neumann HA, Ramaekers FC. Human follicular stem cells: their presence in plucked hair and follicular cell culture. Br J Dermatol 2004;150:860-8.
42. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
43. Kunzmann A, Liu D, Annett K, et al. Flow-cytometric assessment of cellular poly(ADP-ribosyl)ation capacity in peripheral blood lymphocytes. Immun Ageing 2006;3:8.
44. Yang SX, Kummar S, Steinberg SM, et al. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 2009;8:2004-9.
45. Kinders RJ, Hollingshead M, Khin S, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 2008;14:6877-85.
46. Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, Camphausen K. High throughput evaluation of γ-H2AX. Radiat Oncol 2009;4:31.
47. Garty G, Chen Y, Salerno A, et al. The RABIT: a rapid automated biodosimetry tool for radiological triage. Health Phys 2010;98:209-17.
48. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010;16:4527-31.
49. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9.
50. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-73.
51. Hochhauser D, Meyer T, Spanswick VJ, et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009;15:2140-7.
52. Karp JE, Flatten K, Feldman EJ, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009;113:4841-52.
53. Qvarnstrom OF, Simonsson M, Johansson KA, Nyman J, Turesson I. DNA double strand break quantification in skin biopsies. Radiother Oncol 2004;72:311-7. (Pubitemid 39265385)
54. Sak A, Grehl S, Erichsen P, et al. γ-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol 2007;83:639-52.
55. Geisel D, Heverhagen JT, Kalinowski M, Wagner HJ. DNA double-strand breaks after percutaneous transluminal angioplasty. Radiology 2008;248:852-9.
56. Kuefner MA, Grudzenski S, Schwab SA, et al. DNA double-strand breaks and their repair in blood lymphocytes of patients undergoing angiographic procedures. Invest Radiol 2009;44:440-6.
57. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005;58:1009-15.
58. Porcedda P, Turinetto V, Brusco A, et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A 2008;73:508-16.
59. Porcedda P, Turinetto V, Orlando L, et al. Two-tier analysis of histone H2AX phosphorylation allows the identification of Ataxia Telangiectasia heterozygotes. Radiother Oncol 2009;92:133-7.
60. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
61. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
62. Sedelnikova OA, Bonner WM. γH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006;5:2909-13.
63. Yu T, MacPhail SH, Banath JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 2006;5:935-46. (Pubitemid 44160591)
64. Wasco MJ, Pu RT. Utility of antiphosphorylated H2AX antibody (γ-H2AX) in diagnosing metastatic renal cell carcinoma. Appl Immunohistochem Mol Morphol 2008;16:349-56.
65. Ishida J, Yamamoto H, Kido Y, et al. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg Med Chem 2006;14:1378-90.
66. Kopetz SMM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose (PARP) in subjects with advanced solid tumors [abstract]. J Clin Oncol 2008;26:abstr 3577.
67. Mahany JJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors [abstract]. J Clin Oncol 2008;26:abstr 3579.
68. O'Shaugnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-I (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract]. J Clin Oncol 2009;27:abstr 3.
69. Liu X, Palma J, Kinders R, et al. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem 2008;381:240-7.
70. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004;64:7144-9.
71. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
72. Antony S, Agama KK, Miao ZH, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 2007;67:10397-405.
73. Olive PL, Banath JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004;64:5363-9.
74. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004;3:889-900.
75. Rao VA, Agama K, Holbeck S, Pommier Y. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX as a biomarker of DNA damage. Cancer Res 2007;67:9971-9. (Pubitemid 47621247)
76. Krynetskaia N, Xie H, Vucetic S, Obradovic Z, Krynetskiy E. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol 2008;73:260-9. (Pubitemid 350294217)
77. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007;6:1239-48. (Pubitemid 46711987)
78. Kurose A, Tanaka T, Huang X, Traganos F, Dai W, Darzynkiewicz Z. Effects of hydroxyurea and aphidicolin on phosphorylation of ataxia telangiectasia mutated on Ser 1981 and histone H2AX on Ser 139 in relation to cell cycle phase and induction of apoptosis. Cytometry A 2006;69:212-21.
79. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008;283:6572-83.
80. Mirzoeva OK, Kawaguchi T, Pieper RO. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol Cancer Ther 2006;5:2757-66. (Pubitemid 44849002)
81. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, Pommier Y. DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 2005;65:5337-43. (Pubitemid 40827346)
82. Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008;19:3969-81.
83. Liu Y, Tseng M, Perdreau SA, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 2007;67:2685-92.
84. Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007;6:1718-27.
85. Conti C, Leo E, Eichler GS, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 2010;70:4470-80.
86. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42.
87. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-62.
88. Evans JW, Chernikova SB, Kachnic LA, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 2008;68:257-65.
89. Solier S, Pommier Y. The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B, activated DNA. damage response kinases. Cell Cycle 2009;8:1853-9.
90. Solier S, Sordet O, Kohn KW, Pommier Y. Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 2009;29:68-82.
91. Furuta T, Hayward RL, Meng LH, et al. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006;25:2839-49.
92. Mitchell JB, Choudhuri R, Fabre K, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16:2076-84.
93. Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V. Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology 2007;242:244-51. (Pubitemid 44956030)
94. Beels L, Bacher K, De Wolf D, Werbrouck J, Thierens H. γ-H2AX foci as a biomarker for patient X-ray exposure in pediatric cardiac catheterization: are we underestimating radiation risks? Circulation 2009;120:1903-9.
95. Kuefner MA, Hinkmann FM, Alibek S, et al. Reduction of X-ray induced DNA double-strand breaks in blood lymphocytes during coronary CT angiography using high-pitch spiral data acquisition with prospective ECG-triggering. Invest Radiol 2010;45:182-7.
96. Risques RA, Lai LA, Brentnall TA, et al. Ulcerative colitis a disease of accelerated colon aging: evidence From telomere attrition and DNA damage. Gastroenterology 2008;135:410-8.
97. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 2006;23:121-32. (Pubitemid 43963445)
98. Mukherjee B, Kessinger C, Kobayashi J, et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst) 2006;5:575-90.
99. Rossetto D, Truman AW, Kron SJ, Côté J. Epigenetic modification in double-strand break DNA damage signaling and repair. Clin Cancer Res 2010;16:4543-52.
100. Downs JA, Allard S, Jobin-Robitaille O, et al. Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell 2004;16:979-90. (Pubitemid 40018407)
101. van Attikum H, Gasser SM. ATP-dependent chromatin remodeling and DNA double-strand break repair. Cell Cycle 2005;4:1011-4.
102. Unal E, Arbel-Eden A, Sattler U, et al. DNA damage response pathway uses histone modification to assemble a double-strand break-specific cohesin domain. Mol Cell 2004;16:991-1002. (Pubitemid 40018408)
103. Xie A, Puget N, Shim I, et al. Control of sister chromatid recombination by histone H2AX. Mol Cell 2004;16:1017-25. (Pubitemid 40018410)
104. Bassing CH, Alt FW. H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 2004;3:149-53.